Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Malta - English - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - enoxaparin sodium - solution for injection in a pre-filled syringe - enoxaparin sodium 100 mg/ml - antithrombotic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - enoxaparin sodium 100 mg/ml;   - solution for injection - 100 mg/ml - active: enoxaparin sodium 100 mg/ml   excipient: water for injection - prophylaxis of venous thromboembolism in general medical patients bedridden due to acute illnesses including acute heart failure, respiratory failure, severe infections, rheumatic disease. prophylaxis of venous thromboembolic disease, in particular those which may be associated with orthopaedic, general, major colorectal or cancer surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 60 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 20 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 40 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 60 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - enoxaparin sodium - solution for injection - 100mg/1ml